Tianjin TEDA Biomedical Engineering Co Ltd (8189) fair value: what the stock is really worth
We calculate from audited financials what Tianjin TEDA Biomedical Engineering Co Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 2, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Tianjin TEDA Biomedical Engineering Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 2, 2026.
How to read this chart
60‑month range HK$0.0610 – HK$0.6000 · the HK$0.2500 price screens above the HK$0.0800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 2, 2026.
Follow Tianjin TEDA Biomedical Engineering Co in your weekly email
Every Wednesday you see whether Tianjin TEDA Biomedical Engineering Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. It operates through Fertiliser Products, and AI health & elderly care products and services segments.
Show more
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. It operates through Fertiliser Products, and AI health & elderly care products and services segments. The company's biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formulas. It also involved in the provision of integrated elderly and health care; elderly equipment leasing services; elderly-related products sales; warehousing services; processing and licensing of the fertiliser products; sales of gold products for elderly customers, such as gold amulets and bracelets; sales of chips and servers supporting healthcare solutions; research and development of elderly care business; and elderly care consulting, advisory, management, and assessment services. In addition, the company provides and licenses electroencephalography photography (EEG) diagnosis detection services and conducts EEG detection and diagnosis technology services. Further, the company engages in the research, development, manufacture, and application of biomedical science and technology projects; regional soil resources conditioning and remediation research services; provision of soil environmental quality standards research services; development and application of AI medical large model and MaaS platform; AI life and health project expansion; and data cleaning, database, and data intelligence analysis full-process data services. Tianjin TEDA Biomedical Engineering Company Limited was incorporated in 2000 and is headquartered in Tianjin, the People's Republic of China.
Stock analysis
Tianjin TEDA Biomedical Engineering Co Ltd (8189) currently trades at HK$0.2500, while our model-based Fair Value estimate is HK$0.0800, 68.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 89/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tianjin TEDA Biomedical Engineering Co Ltd reported revenue of 509M CNY in FY2025 versus 476M CNY in FY2021, a compound +1.7%/yr. Reported net income was −88.5M CNY in FY2025.
Key figures
Market cap HK$520M (≈ $66.3M) · P/S ratio 0.56 · Net margin −17.4% · Return on equity −729% · Return on assets (EBIT) −6.6% · Operating margin −20.6% · Revenue (TTM) 523M CNY · Revenue growth (YoY) +7.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).
What moves the price
The share trades about 40% below its 52-week high and 105% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 17% fair-value upside, at −68%, 8189 screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic). Over 10 years: +0.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.9% (2020) → −4.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Tianjin TEDA Biomedical Engineering Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 178 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−68.0% · Bottom 25%
Profitability
Return on assets−14.2% · Bottom 25%
Net margin (TTM)−17.4% · Bottom 25%
Operating margin (TTM)−20.6% · Bottom 25%
Growth and dividend
Revenue growth7.0% · Above median
Valuation Multiplesvs Agricultural Inputs median · lower = cheaper
P/B5.42× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.13× · Cheapest 25%
PEG1.80× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 22
FUTURE (revenue growth)35· sector 26
PAST (return on equity)0· sector 24
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Tianjin TEDA Biomedical Engineering Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8189
Frequently asked questions
Is Tianjin TEDA Biomedical Engineering Co Ltd (8189) overvalued or undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.0800 versus a price of HK$0.2500, about −68% upside (overvalued).
What is the fair value of 8189?
Our model-based fair value for Tianjin TEDA Biomedical Engineering Co Ltd is HK$0.0800 (as of Jul 2, 2026), built from audited fundamentals. The current price: HK$0.2500.
What is the quality score of 8189?
Tianjin TEDA Biomedical Engineering Co Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Our model-based price target is the fair value of HK$0.0800 (as of Jul 2, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Tianjin TEDA Biomedical Engineering Co Ltd stock forecast for 2026?
Our models put fair value at HK$0.0800, about −68% upside versus a price of HK$0.2500 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Tianjin TEDA Biomedical Engineering Co Ltd reported trailing-twelve-month revenue of about 523M CNY (latest available figure, as of Jul 2, 2026).
What is the intrinsic value of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tianjin TEDA Biomedical Engineering Co Ltd it is HK$0.0800 per share (as of Jul 2, 2026), against a price of HK$0.2500. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Tianjin TEDA Biomedical Engineering Co Ltd stock overvalued or undervalued in 2026?
As of Jul 2, 2026, 8189 trades above its calculated fair value: price HK$0.2500, fair value HK$0.0800, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8189?
No. The price is what the market pays today (HK$0.2500); the fair value is what the company's own numbers justify (HK$0.0800). For Tianjin TEDA Biomedical Engineering Co Ltd the two are HK$0.1700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tianjin TEDA Biomedical Engineering Co Ltd worth?
The market values Tianjin TEDA Biomedical Engineering Co Ltd at about HK$520M (market capitalisation, as of Jul 2, 2026). Per share that is HK$0.2500; our models calculate a fair value of HK$0.0800 per share.
What is the PEG ratio of 8189?
The PEG ratio of Tianjin TEDA Biomedical Engineering Co Ltd is 1.80 (P/E divided by earnings growth, as of Jul 2, 2026). That is above 1, so the growth is already paid for in the price.
How far is 8189 from its 52-week high?
Tianjin TEDA Biomedical Engineering Co Ltd trades at HK$0.2500, about 40% below its 52-week high of HK$0.4150 and 105% above the low of HK$0.1220 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0800 is for.
Which stocks are comparable to Tianjin TEDA Biomedical Engineering Co Ltd?
From the same area (Basic Materials) we also value Corteva, Inc, Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tianjin TEDA Biomedical Engineering Co Ltd stock attractive at the current price?
The data as of Jul 2, 2026: price HK$0.2500, calculated fair value HK$0.0800 (−68%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8189 calculated?
We run Tianjin TEDA Biomedical Engineering Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.0800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Tianjin TEDA Biomedical Engineering Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The closing price on Sep 30, 2026 was HK$0.2500. Our model-based fair value is HK$0.0800, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tianjin TEDA Biomedical Engineering Co Ltd right now?
Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Tianjin TEDA Biomedical Engineering Co Ltd
How large is the market capitalisation of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The market capitalisation of Tianjin TEDA Biomedical Engineering Co Ltd is HK$520M (≈ $66.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The price-to-sales ratio of Tianjin TEDA Biomedical Engineering Co Ltd is 0.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The net margin of Tianjin TEDA Biomedical Engineering Co Ltd is −17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The return on equity (ROE) of Tianjin TEDA Biomedical Engineering Co Ltd is −729% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
On an EBIT basis the return on assets of Tianjin TEDA Biomedical Engineering Co Ltd is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
The operating margin of Tianjin TEDA Biomedical Engineering Co Ltd is −20.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Revenue at Tianjin TEDA Biomedical Engineering Co Ltd is growing +7.0% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
Earnings per share at Tianjin TEDA Biomedical Engineering Co Ltd are growing +225% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tianjin TEDA Biomedical Engineering Co Ltd (8189) generate?
The free cash flow of Tianjin TEDA Biomedical Engineering Co Ltd is −62.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tianjin TEDA Biomedical Engineering Co Ltd (8189) carry?
The net debt of Tianjin TEDA Biomedical Engineering Co Ltd is 80.6M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tianjin TEDA Biomedical Engineering Co Ltd in the live analysis
One click puts Tianjin TEDA Biomedical Engineering Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
